Skip to main content
Equibles

PAR · Par Drugs And Chemicals Limited · Financials

Use PAR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PAR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
119.00 INR +0.66 (+0.56%) At close · Nov 13
Rebalance outlook locked
Market Cap
1.46B INR
Shares
12.30M
Volume · Nov 13 5898 Avg daily vol (3M) 63.21K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
1.04B +2.7%
FY2026 Revenue FY2022–FY2026
Net Income
131.09M -1.9%
FY2026 Net Income FY2022–FY2026
Operating Cash Flow
164.32M +1.7%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022
INR 1.08B 1.04B 1.01B 956.4M 957.49M 750.74M
INR 37.67M 37.03M 36.47M 34.36M 32.33M 32.81M
INR 941K 1.27M 821K 1.07M 1.33M 4.54M
INR 171.47M 173.02M 179.23M 195.17M 150.79M 127.03M
INR 41.56M 41.93M 45.65M 50.16M 37.45M 34.88M
INR 129.92M 131.09M 133.58M 145.01M 113.34M 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 15.38M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.